ImpriMed to Present Ex Vivo Drug Sensitivity Data in Acute Myeloid Leukemia in Oral Presentation at American Society of Hematology Annual Meeting
Studies Demonstrate xCellSense® Platform's Ability to Predict Clinical Response and Enable Patient Stratification for Drug Development. ImpriMed, a precision oncology CRO specializing in ex vivo drug sensitivity testing for hematologic malignancies, announced today that it has been selected to present two significant research studies at the 67th American Society of Hematology (ASH) Annual Meeting and […]